These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 31774256

  • 1. Pulmonary manifestations in young Gaucher disease patients: Phenotype-genotype correlation and radiological findings.
    Gawad Tantawy AA, Moneam Adly AA, Madkour SS, Salah El-Din NY.
    Pediatr Pulmonol; 2020 Feb; 55(2):441-448. PubMed ID: 31774256
    [Abstract] [Full Text] [Related]

  • 2. Cognitive decline and depressive symptoms: early non-motor presentations of parkinsonism among Egyptian Gaucher patients.
    Tantawy AAG, Adly AAM, Abdeen MSED, Salah NY.
    Neurogenetics; 2020 Jul; 21(3):159-167. PubMed ID: 32215803
    [Abstract] [Full Text] [Related]

  • 3. Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients.
    El-Beshlawy A, Ragab L, Youssry I, Yakout K, El-Kiki H, Eid K, Mansour IM, Abd El-Hamid S, Yang M, Mistry PK.
    J Inherit Metab Dis; 2006 Feb; 29(1):92-8. PubMed ID: 16601874
    [Abstract] [Full Text] [Related]

  • 4. Clinical-genetic characteristics and treatment outcomes of Turkish children with Gaucher disease type 1 and type 3: A sixteen year single-center experience.
    Gumus E, Karhan AN, Hizarcioglu-Gulsen H, Demir H, Ozen H, Saltik Temizel IN, Dokmeci Emre S, Yuce A.
    Eur J Med Genet; 2021 Nov; 64(11):104339. PubMed ID: 34500086
    [Abstract] [Full Text] [Related]

  • 5. Vascular endothelial growth factor (VEGF), tissue inhibitors of metalloproteinase-1 (TIMP-1) and nail fold capillaroscopy changes in children and adolescents with Gaucher disease; relation to residual disease severity.
    Salah NY.
    Cytokine; 2020 Sep; 133():155120. PubMed ID: 32535335
    [Abstract] [Full Text] [Related]

  • 6. Lung involvement and enzyme replacement therapy in Gaucher's disease.
    Goitein O, Elstein D, Abrahamov A, Hadas-Halpern I, Melzer E, Kerem E, Zimran A.
    QJM; 2001 Aug; 94(8):407-15. PubMed ID: 11493717
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [High dose of enzyme replacement therapy was successful for the pulmonary involvement in a case of type 2 Gaucher disease].
    Arai N, Uematsu M, Abe Y, Fukuyo N, Wakusawa K, Kikuchi A, Sakamoto O, Ohura T, Tsuchiya S.
    No To Hattatsu; 2010 Jan; 42(1):45-9. PubMed ID: 23858612
    [Abstract] [Full Text] [Related]

  • 9. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
    El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, Batista JL, Cox GF, Mistry PK.
    Mol Genet Metab; 2017 Jan; 120(1-2):47-56. PubMed ID: 28040394
    [Abstract] [Full Text] [Related]

  • 10. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 11. Different features of lung involvement in Niemann-Pick disease and Gaucher disease.
    Gülhan B, Ozçelik U, Gürakan F, Güçer S, Orhan D, Cinel G, Yalçin E, Ersöz DD, Kiper N, Yüce A, Kale G.
    Respir Med; 2012 Sep; 106(9):1278-85. PubMed ID: 22784405
    [Abstract] [Full Text] [Related]

  • 12. Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacement.
    Lebel E, Elstein D, Peleg A, Reinus C, Zimran A, Amir G.
    Am J Clin Pathol; 2013 Jul; 140(1):91-6. PubMed ID: 23765538
    [Abstract] [Full Text] [Related]

  • 13. Evoked potentials and neurocognitive functions in pediatric Egyptian Gaucher patients on enzyme replacement therapy: a single center experience.
    Tantawy AA, Sherif EM, Adly AA, Hassanine S, Awad AH.
    J Inherit Metab Dis; 2013 Nov; 36(6):1025-37. PubMed ID: 23508695
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The role of high density lipoprotein in Type 1 Gaucher disease.
    Watad S, Abu-Saleh N, Yousif A, Agbaria A, Rosenbaum H.
    Blood Cells Mol Dis; 2018 Feb; 68():43-46. PubMed ID: 27876360
    [Abstract] [Full Text] [Related]

  • 17. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients.
    Sechi A, Deroma L, Dardis A, Ciana G, Bertin N, Concolino D, Linari S, Perria C, Bembi B.
    Mol Genet Metab; 2014 Nov; 113(3):213-8. PubMed ID: 25127542
    [Abstract] [Full Text] [Related]

  • 18. Gaucher disease with pulmonary involvement in a 6-year-old girl: report of resolution of radiographic abnormalities on increasing dose of imiglucerase.
    Lee SY, Mak AW, Huen KF, Lam ST, Chow CB.
    J Pediatr; 2001 Dec; 139(6):862-4. PubMed ID: 11743514
    [Abstract] [Full Text] [Related]

  • 19. Generation of osteoclasts from type 1 Gaucher patients and correlation with clinical and genetic features of disease.
    Reed MC, Bauernfreund Y, Cunningham N, Beaton B, Mehta AB, Hughes DA.
    Gene; 2018 Dec 15; 678():196-206. PubMed ID: 30099023
    [Abstract] [Full Text] [Related]

  • 20. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep 15; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.